IDEXX Laboratories, Inc.

IDXX Healthcare Diagnostics & Research

IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024.

Revenue
+9.86%
EPS
+17.3%
Free cash flow
+17.6%
Total debt
−28.6%

Quarter to September 2026, against a year earlier

677.29 6.58 +0.98%
Market cap
$52.8B
P/E
44.8×
Fwd P/E
37.3×
Dividend yield
—
F-score
8/9
Altman Z
24.09
Beneish M
−2.50
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26
Piotroski F-Score

+8 more TTM periods

8 8 9 9
ROE
66.20% 72.92% 74.21% 68.93%
ROA
31.89% 33.19% 33.65% 33.33%
ROIC
45.33% 48.68% 48.87% 46.00%
Return on Tangible Assets
104.65% 122.43% 119.33% 122.14%
Average Days of Receivables
46.85 49.55 50.27 48.21
Free Cash Flow per Share
11.89 13.28 15.67 16.49
Free Cash Flow
956.58 1,058.11 1,237.09 1,300.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026